What KOLs Revealed? Lilly’s Retatrutide as an Emerging Treatment Choice in NASH & Obesity

The domain of Non-alcoholic steatohepatitis (NASH) and Obesity treatment is continually evolving, with new discoveries and insights that are reshaping our understanding of how to best combat this liver disease. One of the most talked-about developments is Lilly’s retatrutide, whose unprecedented results in recent studies have generated a buzz in the medical community. In this article, we dive deep into the potential of Lilly’s retatrutide, weighing its advantages and possible considerations.

Table 1: Lilly’s Retatrutide – Quick Glance by Mellalta Meets

Attributes	Outcomes
Weight Loss Impact	Rivals bariatric surgery with a weight loss of -7.2% to -24.2% at varied weeks
Impact on Liver Fat	93% of patients witnessed <5% liver fat content
Considerations	Long-term adverse effects including GI issues and cardiac concerns
Advantages over GLP-1 Products	Demonstrated impact on liver fat, which previous GLP-1 products lacked
Target Audience	Suitable for patients requiring bariatric-level weight loss; alternatives for others

Lilly’s Retatrutide: More than Just Weight Loss

KOL’s Opinion

If patients can achieve a weight loss exceeding 10%, it becomes feasible to address the three primary NASH domains: liver steatosis, inflammation, and fibrosis.

The unique triple agonism (GLP-1/GIP/glucagon) of retatrutide undeniably showcases an additive effect, leading to weight loss percentages that are comparable to bariatric surgery outcomes.

Liver Fat Reduction: Retatrutide’s Defining Impact

Unlike other GLP-1 obesity products, which had no demonstrated effect on liver fat, retatrutide has shown significant strides. An impressive 93% of patients on retatrutide achieved liver fat content below 5%, meeting the criterion for NAFLD resolution. Furthermore, 100% of patients experienced over 30% liver fat reduction, a notable predictor for fibrosis impact.

The mechanism behind this is the targeted approach to glucagon receptors, predominant in the liver. This impacts fat oxidation in liver mitochondria, thereby potentially inhibiting NAFLD/NASH progression.

Retatrutide and Fibrosis

While the results have been remarkable, the KOLs remain cautious. To note, the study population lacked fibrosis, so claims about retatrutide’s potential to reverse fibrosis should be considered preliminary at best.

Key Considerations with Retatrutide

While retatrutide’s results are promising, there are significant considerations:

Adverse Effects: Serious GI issues and potential cardiac arrhythmias are of concern.
Patients with Diabetes: Retatrutide’s effect on A1C could be problematic, given its interaction with the glucagon receptor (GCGR).
Cardiac Risk Factors: There’s potential lowering of HDL (“good” cholesterol), which might pose another cardiac risk.

Future Landscape and Treatment Choices

As we progress, options will allow for greater selectivity:

For patients requiring intense weight loss equivalent to bariatric surgery, retatrutide seems appropriate.
Most patients, with moderate obesity, might benefit from less aggressive options, indicating the relevance of single and dual-agonists.

KOL anticipates GLP-1 biosimilars to reduce the cost of weight loss therapy in the future. However, the ultimate objective remains: improving cardiac risk factors and liver health, emphasizing the continued importance of treatments directly impacting inflammation and fibrosis.

Lilly’s retatrutide has undeniably transformed discussions surrounding NASH treatment. While its potential is evident, it’s crucial to approach with balanced optimism, considering long-term effects and specific patient needs. With ongoing research, the path to a comprehensive NASH treatment plan seems clearer than ever.

Mellalta Meets How Nanobiotixs Breakthrough NBTXR3 is Poised to Radically Transform the LA-HNSCC Landscape

How Acute myeloid leukaemia (AML) Clinical Landscape is transforming for IDH1 or IDH2 mutated patients? Key comments from ASH 2022

Mellalta Meets Analyst Dec 20, 2022 Business

Acute myeloid leukaemia is a genetically heterogeneous hematologic malignancy in which approximately 8% and 12% of acute myeloid leukemias harbour an IDH1 or IDH2 mutation,

Cart